

Hypertension in adults (update) Committee meeting 3

Date: 11/12/2017

Location: NGC Boardroom, RCP, 11 St Andrew's Place, London NW1 4LE

Minutes: Confirmed

NICE National Institute for
Health and Care Excellence

Committee members present:	
Anthony Wierzbicki (Chair)	(Present for notes 1–5)
Liz Clark	(Present for notes 1–5)
Elizabeth Denver	(Present for notes 1–5)
Mark Glover	(Present for notes 1–5)
Judith Magowan	(Present for notes 1–5)
Terry McCormack	(Present for notes 1–5)
Irene McGill	(Present for notes 1–5)
Richard McManus	(Present for notes 1–5)
Lucy Pollock	(Present for notes 1–5)
Mark Shapley	(Present for notes 1–5)
Alison Warren	(Present for notes 1–5)
Bryan Williams	(Present for notes 1–5)

In attendance:		
Serena Carville	Guideline Lead, NGC	(Present for notes 1–5)
Margaret Constanti	Senior Health Economist, NGC	(Present for notes 1–5)
Lina Gulhane	Head of Information Specialist, NGC	(Present for notes 1–5)
Qudsia Malik	Senior Research Fellow, NGC	(Present for notes 1–5)
Natalie Wood	Project Manager, NGC	(Present for notes 1–5)

Observer(s):		
Katherine Jones	Research Fellow, NGC	(Present for notes 1–5)

Apologies:	
Catharine Baden-Daintree	Senior Medical Editor, NICE
Caroline Kier	Guideline Commissioning Manager, NICE
Jane Lynn	Business Analyst, NICE
Rebecca Boffa	Research Fellow, NGC
Meredith Faust	Project Manager, NGC
Beatriz Ferrer-Quiles	Information Specialist, NGC
Christopher Floyd	Clinical Trainee, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the third meeting on Hypertension in adults. The committee members and attendees introduced themselves.

No members of the public asked to observe the meeting.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included the evidence for the first-line treatment review and finalising the monitoring and target protocols.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was first-line treatment, monitoring treatment and treatment targets.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Terry McCormack	Honorary Reader in Primary Care Medicine, Hull York Medical School; Principal in General Practice, Whitby Practice	Appointed to the VTE guideline committee	Personal non-financial non-specific	Declare and participate
		The Whitby Group Practice research fund received a speaker fee from Boehringer Ingelheim for a	Non-personal financial non-specific	Declare and participate

		talk I gave on atrial fibrillation management at a Primary Care Cardiovascular Society meeting.		
Alison Warren	Consultant Pharmacist Cardiology, Brighton and Sussex University Hospitals NHS Trust and Brighton and Hove CCG	Received an educational sponsorship from Novartis to attend the Annual British Society of Heart failure Meeting in London November 2017	Personal financial non-specific	Declare and participate

The Chair and a senior member of the Developer's team noted both Richard McManus and Bryan Williams have published on monitoring blood pressure. These papers did not exclude RMM or BW from discussion. The interests declared of the other committee members did not prevent the attendees from fully participating in the meeting.

3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Questions and discussion

- A. SC presented the evidence for the review question: Is monotherapy or combination antihypertensive therapy more clinically and cost effective for first-line treatment for hypertension? The committee reviewed and discussed the evidence.
- B. QM led a discussion on the draft protocol for monitoring hypertension. The committee discussed and finalised the draft protocol.
- C. MC presented several questions for the committee to consider regarding the health economics for the initiation of treatment review question: At what blood pressure and/or cardiovascular disease risk threshold should antihypertensive drug treatment be initiated for adults with hypertension? The committee then

discussed and finalised the draft protocol for this review question.
--

5. Any other business

None.

Date of next meeting: 24/01/2018

Location of next meeting: Linacre Room, RCP